Early B cell factor 1 (EBF1) is one of the key transcription factors required for orchestrating B-cell lineage development. Although studies have shown that Ebf1 haploinsufficiency is involved in the development of leukemia, no study has been conducted that characterizes the global effect of Ebf1 heterozygosity on the proteome of pro-B lymphocytes. Here, we employ both data independent acquisition (DIA) and shotgun data dependent acquisition (DDA) workflows for profiling proteins that are differently expressed between Ebf1 and Ebf1 cells. Both DDA and DIA were able to reveal the downregulation of the EBF1 transcription factor in Ebf1 pro-B lymphocytes. Further examination of differentially expressed proteins by DIA revealed that, similar to EBF1, the expression of other B-cell lineage regulators, such as TCF3 and Pax5, is also downregulated in Ebf1 heterozygous cells. Functional DIA analysis of differentially expressed proteins showed that EBF1 heterozygosity resulted in the deregulation of at least eight transcription factors involved in lymphopoiesis and the deregulation of key proteins playing crucial roles in survival, development, and differentiation of pro-B lymphocytes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jproteome.7b00369 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to think about acute leukemia of ambiguous lineage.
Hematology Am Soc Hematol Educ Program
December 2024
UT Southwestern Medical Center, BioCenter, Dallas, TX.
Classification of acute leukemia involves assigning lineage by resemblance of blasts to normal progenitor cells. This approach provides descriptive information that is useful for disease monitoring, provides clues to pathogenesis, and can help to select effective chemotherapeutic regimens. Acute leukemias of ambiguous lineage (ALAL) are those leukemias that either fail to show evidence of myeloid, B-lymphoid, or T-lymphoid lineage commitment or show evidence of commitment to more than 1 lineage, including mixed-phenotype acute leukemia (MPAL).
View Article and Find Full Text PDFPotential molecular mechanisms of ETV6-RUNX1-positive B progenitor cell cluster in acute lymphoblastic leukemia revealed by single-cell RNA sequencing.
PeerJ
November 2024
Neurosurgery Department, Jinzhou Central Hospital, Jinzhou, China.
Article Synopsis
- The study aimed to investigate the immune landscape and immune cell roles in the progression of acute lymphoblastic leukemia (ALL), focusing particularly on the ETV6-RUNX1 genetic alteration common in childhood cases.
- Using advanced techniques like single-cell RNA sequencing, researchers analyzed B progenitor cells from bone marrow samples, identifying specific gene expressions and pathways that may drive rapid cell cycle progression in ALL.
- Results highlighted distinct clusters of B progenitor cells, particularly one with amplified genes on chromosome 6p that were linked to increased cell cycle activity, underscoring the complexity of immune interactions in the disease's progression.
Conserved helical motifs in the IKZF1 disordered region mediate NuRD interaction and transcriptional repression.
Blood
January 2025
Medical Research Council Laboratory of Medical Sciences, Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom.
The transcription factor (TF) Ikaros zinc finger 1 (IKZF1) is essential for B-cell development, and recurrently mutated in human B-cell acute lymphoblastic leukemia (B-ALL). IKZF1 has been ascribed both activating and repressive functions via interactions with coactivator and corepressor complexes, but the relative abundance of IKZF1-associated coregulators and their contribution to IKZF1-mediated gene regulation are not well understood. To address this, we performed an unbiased identification of IKZF1-interacting proteins in pre-B cells and found that IKZF1 interacts overwhelmingly with corepressors and heterochromatin-associated proteins.
View Article and Find Full Text PDFCyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress responses.
Haematologica
October 2024
Department for Biological Sciences and Pathobiology, University of Veterinary Medicine, Vienna.
Despite major therapeutic advances in the treatment of acute lymphoblastic leukemia (ALL), resistances and long-term toxicities still pose significant challenges. Cyclins and their associated cyclin-dependent kinases are one focus of cancer research when looking for targeted therapies. We discovered cyclin C as a key factor for B-ALL development and maintenance.
View Article and Find Full Text PDFYY1 knockout in pro-B cells impairs lineage commitment, enabling unusual hematopoietic lineage plasticity.
Genes Dev
October 2024
Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;
Article Synopsis
- During B-cell development, the pro-B-cell stage is crucial for committing to the B-cell lineage, and the transcription factor YY1 plays a key role in this process.
- Knocking out YY1 at the pro-B-cell stage stops B-cell development and enables these cells to convert into T lineage cells, demonstrating a shift in their genetic expression profiles.
- Research involving various sequencing techniques shows that the loss of YY1 not only affects B lineage commitment but also allows pro-B cells to exhibit flexibility in developing into multiple hematopoietic lineages due to changes in chromatin accessibility.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!